Marlex Pharmaceuticals Inc.

Marlex Pharmaceuticals Inc., doing business as Marlex Pharmaceuticals I, manufactures and supplies generic pharmaceutical tablets to federal healthcare systems as a prime contractor, competing full-and-open with no set-aside designation across 423 awards valued at $404.5 million combined potential value. The company is a minority-owned, Subcontinent Asian American-owned small disadvantaged business headquartered in New Castle, Delaware, structured as a for-profit corporate entity.

Marlex's federal work centers on generic medications sold through indefinite delivery contracts and delivery orders under the Defense Logistics Agency Troop Support Medical medical supply chain and the Department of Veterans Affairs pharmaceutical prime vendor program. The vendor's concrete product portfolio includes prednisone (multiple dosages), haloperidol, methocarbamol, loratadine, cetirizine HCl, thiamine, pyrazinamide, alendronate, ezetimibe, ropinirole HCl, and melatonin tablets in tablet or capsule form. Recent representative work includes a $5.9 million single-award IDC with VA National Acquisition Center for melatonin tablets (September 2026); a $204.8 million GSA Federal Supply Schedule contract for generic pharmaceuticals through February 2030 under Schedule 65 I B; a $14.1 million single-award IDC with VA for ezetimibe 10 mg tablets (April 2024); and multiple delivery orders against DLA Troop Support Medical ranging from single dollars to $34,608 for specific medications such as prednisone 20 mg in 100-count bottles.

Customer concentration is pronounced and stable. The top five funding agencies by count account for 92% of recent awards, led by the Defense Logistics Agency Troop Support Medical at 342 awards ($89.4 million combined potential value) and the Department of Veterans Affairs (across multiple business units) with 53 awards. However, the top-customer ranking by potential value flips notably: VA Veterans Integrated Service Network 12 anchors $240.4 million (11 awards), DLA Troop Support Medical carries $89.4 million (342 awards), and VA National Acquisition Center holds $68.1 million (7 awards). This tension reflects Marlex's strategy of stacking large-dollar IDCs with VA while fulfilling high-volume, small-dollar delivery orders under DLA's medical supply chain.

Marlex holds three primary parent contract vehicles. An Indefinite Delivery Contract (SPE2D020D0008) carries 210 task orders valued at $183 thousand combined potential value. A second IDC (SPM2D012D0005) holds 130 task orders at $64 thousand combined. The GSA Federal Supply Schedule V797P5688X contract supports 45 task orders valued at $826 thousand. All three vehicles are full-and-open; the vendor operates exclusively as a prime contractor with no subcontract footprint across the recent award history.

Activity has accelerated substantially. Awards grew from 6 in 2022 to 42 in 2024 and 93 in 2025, signaling aggressive federal market capture. Fifty awards arrived in 2026 year-to-date. Only one award (valued at $23 thousand) reaches completion within the next twenty-four months, indicating minimal near-term recompete exposure. The combined potential value obligated across all awards stands at $3.6 million (1% of the combined potential value ceiling), typical of IDC-heavy portfolios where awards represent ordering vehicles rather than invoiced revenue.

Work is performed nationwide. The primary NAICS categories reflect the core business: Medicinal and Botanical Manufacturing (342 awards) and Pharmaceutical Preparation Manufacturing (72 awards). The dominant PSC code is Drugs and Biologicals (384 awards). Marlex manufactures and distributes to federal beneficiaries across the Department of Defense, Department of Veterans Affairs, Bureau of Prisons, and Indian Health Service, with all pharmaceutical supplies delivered through established federal healthcare supply chains and vendor programs.